'Been through a lot': New Passage Bio CEO talks about 'rising tide'; Back in business with the FDA, BioMarin finds itself without a CMO
William Chou has a lot on his hands at Passage Bio as the Jim Wilson-founded biotech attempts a rebound following a rough year of executive departures, layoffs and pipeline pruning.
Chou himself recently departed another gene therapy developer that has essentially shuttered. Aruvant, from the Roivant web, ceased clinical development of a lentiviral gene therapy for beta thalassemia after enrolling seven patients, and a preclinical AAV gene therapy for patients with hypophosphatasia, the parent company announced this summer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.